169 related articles for article (PubMed ID: 32228600)
1. Immunogenicity analysis of conserved fragments in Plasmodium ovale species merozoite surface protein 4.
Uwase J; Chu R; Kassegne K; Lei Y; Shen F; Fu H; Sun Y; Xuan Y; Cao J; Cheng Y
Malar J; 2020 Mar; 19(1):126. PubMed ID: 32228600
[TBL] [Abstract][Full Text] [Related]
2. Genetic diversity and immunogenicity of the merozoite surface protein 1 C-terminal 19-kDa fragment of Plasmodium ovale imported from Africa into China.
Xu Q; Liu S; Kassegne K; Yang B; Lu J; Sun Y; Zhong W; Zhang M; Liu Y; Zhu G; Cao J; Cheng Y
Parasit Vectors; 2021 Nov; 14(1):583. PubMed ID: 34819151
[TBL] [Abstract][Full Text] [Related]
3. Low genetic diversity and strong immunogenicity within the apical membrane antigen-1 of plasmodium ovale spp. imported from africa to china.
Lei Y; Shen F; Zhu H; Zhu L; Chu R; Tang J; Yao W; Zhu G; Zhang D; Cao J; Cheng Y
Acta Trop; 2020 Oct; 210():105591. PubMed ID: 32562621
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity analysis of genetically conserved segments in Plasmodium ovale merozoite surface protein-8.
Zhang X; Chu R; Xu S; Fu H; Tang J; Chen L; Shi X; Chen J; Li Y; Zhu G; Han ET; Xuan Y; Cao J; Cheng Y
Parasit Vectors; 2019 Apr; 12(1):164. PubMed ID: 30975200
[TBL] [Abstract][Full Text] [Related]
5. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
[TBL] [Abstract][Full Text] [Related]
6. Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
Perraut R; Varela ML; Joos C; Diouf B; Sokhna C; Mbengue B; Tall A; Loucoubar C; Touré A; Mercereau-Puijalon O
Vaccine; 2017 Dec; 35(48 Pt B):6720-6726. PubMed ID: 29042203
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms analysis of the Plasmodium ovale tryptophan-rich antigen gene (potra) from imported malaria cases in Henan Province.
Zhou R; Liu Y; Li S; Zhao Y; Huang F; Yang C; Qian D; Lu D; Deng Y; Zhang H; Xu B
Malar J; 2018 Mar; 17(1):127. PubMed ID: 29566685
[TBL] [Abstract][Full Text] [Related]
8. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
[TBL] [Abstract][Full Text] [Related]
9. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.
Wang L; Richie TL; Stowers A; Nhan DH; Coppel RL
Infect Immun; 2001 Jul; 69(7):4390-7. PubMed ID: 11401978
[TBL] [Abstract][Full Text] [Related]
10. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol.
Rainczuk A; Smooker PM; Kedzierski L; Black CG; Coppel RL; Spithill TW
Vaccine; 2003 Jun; 21(21-22):3030-42. PubMed ID: 12798647
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii.
Kedzierski L; Black CG; Coppel RL
Mol Biochem Parasitol; 2000 Jan; 105(1):137-47. PubMed ID: 10613706
[TBL] [Abstract][Full Text] [Related]
12. Specificity of the IgG antibody response to Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, and Plasmodium ovale MSP1
Priest JW; Plucinski MM; Huber CS; Rogier E; Mao B; Gregory CJ; Candrinho B; Colborn J; Barnwell JW
Malar J; 2018 Nov; 17(1):417. PubMed ID: 30413163
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
[TBL] [Abstract][Full Text] [Related]
14. A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.
Wilson KL; Pouniotis D; Hanley J; Xiang SD; Ma C; Coppel RL; Plebanski M
Front Immunol; 2019; 10():331. PubMed ID: 30930890
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism analysis of propeller domain of k13 gene in Plasmodium ovale curtisi and Plasmodium ovale wallikeri isolates original infection from Myanmar and Africa in Yunnan Province, China.
Chen M; Dong Y; Deng Y; Xu Y; Liu Y; Zhang C; Huang H
Malar J; 2020 Jul; 19(1):246. PubMed ID: 32660505
[TBL] [Abstract][Full Text] [Related]
16. Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 8 in patients with P. vivax infection.
Cheng Y; Wang B; Changrob S; Han JH; Sattabongkot J; Ha KS; Chootong P; Lu F; Cao J; Nyunt MH; Park WS; Hong SH; Lim CS; Tsuboi T; Han ET
Malar J; 2017 May; 16(1):211. PubMed ID: 28532483
[TBL] [Abstract][Full Text] [Related]
17. Differences in epitope recognition, isotype and titer of antisera to Plasmodium falciparum merozoite surface protein 4 raised by different modes of DNA or protein immunization.
Wang L; Menting JG; Black CG; Stowers A; Kaslow DC; Hoffman SL; Coppel RL
Vaccine; 2000 Nov; 19(7-8):816-24. PubMed ID: 11115704
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
19. Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.
Wang L; Black CG; Marshall VM; Coppel RL
Infect Immun; 1999 May; 67(5):2193-200. PubMed ID: 10225874
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
